DYN
$18.66
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, includi...
Recent News
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data
Dyne Therapeutics (NasdaqGS:DYN) has initiated the Phase 3 Harmonia trial of DYNE-101 in myotonic dystrophy type 1, following alignment with the FDA on the study design. The Harmonia trial is a pivotal study focused on clinically meaningful endpoints tied to key functional impairments in myotonic dystrophy type 1. New long term data from the Phase 1/2 DELIVER trial of DYNE-251 in Duchenne muscular dystrophy report improvements in cardiac and lung function. These updates highlight clinical...
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 11 Best Day Trading Stocks to Buy Now. Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs. The firm revealed that it planned to submit an accelerated application for its DMD drug to target a launch in the first quarter […]
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 Stocks Investors Are Watching. Dyne Therapeutics saw its share prices jump by 11.81 percent on Tuesday to close at $19.78 apiece, after an investment firm reiterated a triple-digit upside potential for its stock. In a market report, Jefferies reiterated its “buy” issuance for Dyne Therapeutics Inc. […]
A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical Progress
Dyne Therapeutics (DYN) is back in focus after Q4 2025 results showed a loss per share that came in ahead of expectations, alongside continued net losses and detailed progress in its late stage pipeline. See our latest analysis for Dyne Therapeutics. Despite Q4 earnings beating expectations, Dyne Therapeutics' recent share price has eased. The 30 day share price return is 19.83% and the 90 day share price return is 25.05%, while the 1 year total shareholder return of 24.18% indicates that...
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.